News & Blog
News & Blog
Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia
January 2024 – Advocacy Newsletter
CHMP Issues Positive Opinion for Biogen’s SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia, a Rare Neurodegenerative Disease
Biogen Completes Acquisition of Reata Pharmaceuticals
Design Therapeutics Provides Pipeline Update and Reports Second Quarter 2023 Financial Results
Initial Data from Phase 1 Multiple-Ascending Dose Trial of DT-216 for Friedreich Ataxia Showed Significant Increase in FXN mRNA Levels i...
2023 FARA Fellows
The FARA Fellow Program recognizes young investigators who will commit their early career to FA research and want to grow their profile ...
Larimar Therapeutics Receives FDA Clearance
Larimar Therapeutics Receives FDA Clearance to Proceed to 50 mg Cohort in CTI-1601’s Phase 2 Friedreich’s Ataxia Trial and to Initiate Open Label Extension Trial
Lexeo Therapeutics Announces Completion of First Cohort and Dosing in Second Cohort in SUNRISE-FA, a Phase 1/2 Clinical Trial of LX2006 for the Treatment of Friedreich’s Ataxia Cardiomyopathy
FARA Celebrates the 15th Annual Ataxian Athlete Initiative (AAI) for People with Ataxia